24 May 2016 - Daklinza is approved in Canada in combination with other agents for the treatment of chronic hepatitis C patients with HIV co-infection, advanced cirrhosis and post-liver transplant HCV recurrence.

Bristol-Myers Squibb Canada today announced Health Canada’s approval of Daklinza (daclatasvir), in combination with sofosbuvir (with or without ribavirin) for 12 weeks in the treatment of chronic hepatitis C (CHC) in adult patients with hepatitis C virus (HCV) genotypes 1, 2 or 3 in three difficult-to-treat populations, including patients with HIV-1 co-infection, patients with compensated or decompensated cirrhosis and patients with HCV recurrence after liver transplantation.

For more details, go to: http://www.bmscanada.ca/en/news/release/health-canada-approves-daklinza-daclatasvir-for-difficult-to-treat-hepatitis-c-patient-populations